Abstract:Background: Allergic drug reaction or drug allergy is an immunologically mediated drug hypersensitivity reaction (DHR). G-protein coupled receptors (GPCRs) are common drug targets and communicate extracellular signals that initiate cellular responses. Recent evidence shows that GPCR MRGPRX2 is of major importance in IgE-independent pseudo-allergic DHRs based on the suspected interactions between many FDA-approved peptidergic compounds and MRGPRX2. Objective: Our aim was to uncover novel MRGPRX2-selective and -potent agonists as drug candidates responsible for clinical features of pseudo-allergic DHRs. Methods: We conducted a primary high-throughput screening (HTS), coupled with mutagenesis targeting the MRGPRX2 N62S mutation, on a panel of 3,456 library compounds. We discovered pharmacologically active hit compounds as agonists of the MRGPRX2 protein according to high degrees of potency evaluated by the calcium response and validated by the degranulation assay. Using the molecular tool Forge, we also characterized the structure-activity relationship shared by identified hit compounds. Results: The alternative allele of single nucleotide polymorphism rs10833049 (N62S) in MRGPRX2 demonstrated loss-of-function property in response to substance P and antineoplastic agent daunorubicin hydrochloride. We applied a unique assay system targeting the N62S mutation to the HTS and identified 84 MRGPRX2-selective active hit compounds representing diverse classes according to primary drug indications. The top five highly represented groups included fluoroquinolone and non-fluoroquinolone antibiotics; antidepressive/antipsychotic; antihistaminic and antineoplastic agents. We classified hit compounds into 14 clusters representing a variety of chemical and drug classes beyond those reported, such as opioids, neuromuscular blocking agents, and fluoroquinolones. We further demonstrated MRGPRX2-dependent degranulation in the human mast cell line LAD2 cells induced by three novel agonists representing the non-fluoroquinolone antibiotics (bacitracin A), anti-allergic agents (brompheniramine maleate) and tyrosine-kinase inhibitors (imatinib mesylate). Conclusion: Our findings could facilitate the development of interventions for personalized prevention and treatment of DHRs, as well as future pharmacogenetic investigations of MRGPRX2 in relevant disease cohorts.

Biological screening of a unique drug library targeting MRGPRX2

Novel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction

Development of an Environmentally Sensitive Fluorescent Peptide Probe for MrgX2 and Application in Ligand Screening of Peptide Antibiotics.

Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists

Synthesis and evaluation of new potential anti-pseudo-allergic agents

MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo‐allergic and anaphylactoid reactions

Cell-based phenotypic screening of mast cell degranulation unveils kinetic perturbations of agents targeting phosphorylation

In silico design of novel probes for the atypical opioid receptor MRGPRX2

“Relative Symmetry with Electronegativity of Different Key-Groups” Strategy for MRGPRX2 Antagonist Design and Its Effect on Antigen-Induced Pulmonary Inflammation

MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs

Patient Characteristics Associated With Reactions to Mrgprx2-Activating Drugs in an Electronic Health Record-Linked Biobank

MRGPRX2 and Adverse Drug Reactions

Typical Antimicrobials Induce Mast Cell Degranulation and Anaphylactoid Reactions Via MRGPRX2 and Its Murine Homologue MRGPRB2

Ligands and Signaling of Mas-Related G Protein-Coupled Receptor-X2 in Mast Cell Activation.

Structure, function and pharmacology of human itch receptor complexes

MrgX2-SNAP-tag/cell Membrane Chromatography Model Coupled with Liquid Chromatography-Mass Spectrometry for Anti-Pseudo-allergic Compound Screening in Arnebiae Radix.

Inhibition of MRGPRX2 but not FcεRI or MrgprB2-mediated mast cell degranulation by a small molecule inverse receptor agonist

High-throughput Screening of Novel Antagonists on Melanin-Concentrating Hormone Receptor-1

Differential MRGPRX2-dependent activation of human mast cells by polymyxins and octapeptins

Beyond Allergies—Updates on The Role of Mas-Related G-Protein-Coupled Receptor X2 in Chronic Urticaria and Atopic Dermatitis

A novel MRGPRX2-targeting antagonistic DNA aptamer inhibits histamine release and prevents mast cell-mediated anaphylaxis